Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens

Michelle Degnin, Anupriya Agarwal, Katherine Tarlock, Soheil Meshinchi, Brian Druker, Cristina E. Tognon

Research output: Contribution to journalArticle

Abstract

The ability to assess antileukemic drug activity on primary patient samples is a powerful tool in determining potential drug targets and selection of therapeutic agents with biological and functional rationale. We previously established small molecule inhibitor screens for use on freshly isolated leukemia cells for this purpose. Here we describe a method that produces functional small molecule inhibitor screening results using cryopreserved primary acute myeloid leukemia cells. This method was established to take advantage of biorepositories containing archival material, such as those established by the Children's Oncology Group, and to enable validation of potential pathway dependencies uncovered by genomic analysis. Various conditions used to thaw and culture cryopreserved specimens were assessed for effect on viability, differentiation, and the ability to recapitulate sensitivity results obtained on fresh samples. The most reproducible results were obtained by quick-thawing and culturing samples in cytokine rich media before performing drug screens. Our data suggest that cytokine-enriched media AIDS in maintaining the viability and numbers required to perform functional analysis on cryopreserved leukemia cells. This method can aid in producing informative data on therapeutic targeting and precision medicine efforts in leukemia by making use of biorepositories and bio banks.

Original languageEnglish (US)
Pages (from-to)e359-e366
JournalJournal of Pediatric Hematology/Oncology
Volume39
Issue number7
DOIs
StatePublished - 2017

Fingerprint

Myeloid Cells
Acute Myeloid Leukemia
Leukemia
Pharmaceutical Preparations
Cytokines
Precision Medicine
Acquired Immunodeficiency Syndrome
Therapeutics

Keywords

  • acute myeloid leukemia (AML)
  • biorepositories
  • cryopreservation
  • small molecule inhibitor assays

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens. / Degnin, Michelle; Agarwal, Anupriya; Tarlock, Katherine; Meshinchi, Soheil; Druker, Brian; Tognon, Cristina E.

In: Journal of Pediatric Hematology/Oncology, Vol. 39, No. 7, 2017, p. e359-e366.

Research output: Contribution to journalArticle

Degnin, Michelle ; Agarwal, Anupriya ; Tarlock, Katherine ; Meshinchi, Soheil ; Druker, Brian ; Tognon, Cristina E. / Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens. In: Journal of Pediatric Hematology/Oncology. 2017 ; Vol. 39, No. 7. pp. e359-e366.
@article{bd1cc4421d094d72b6a6cdb2803fb59c,
title = "Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens",
abstract = "The ability to assess antileukemic drug activity on primary patient samples is a powerful tool in determining potential drug targets and selection of therapeutic agents with biological and functional rationale. We previously established small molecule inhibitor screens for use on freshly isolated leukemia cells for this purpose. Here we describe a method that produces functional small molecule inhibitor screening results using cryopreserved primary acute myeloid leukemia cells. This method was established to take advantage of biorepositories containing archival material, such as those established by the Children's Oncology Group, and to enable validation of potential pathway dependencies uncovered by genomic analysis. Various conditions used to thaw and culture cryopreserved specimens were assessed for effect on viability, differentiation, and the ability to recapitulate sensitivity results obtained on fresh samples. The most reproducible results were obtained by quick-thawing and culturing samples in cytokine rich media before performing drug screens. Our data suggest that cytokine-enriched media AIDS in maintaining the viability and numbers required to perform functional analysis on cryopreserved leukemia cells. This method can aid in producing informative data on therapeutic targeting and precision medicine efforts in leukemia by making use of biorepositories and bio banks.",
keywords = "acute myeloid leukemia (AML), biorepositories, cryopreservation, small molecule inhibitor assays",
author = "Michelle Degnin and Anupriya Agarwal and Katherine Tarlock and Soheil Meshinchi and Brian Druker and Tognon, {Cristina E.}",
year = "2017",
doi = "10.1097/MPH.0000000000000946",
language = "English (US)",
volume = "39",
pages = "e359--e366",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens

AU - Degnin, Michelle

AU - Agarwal, Anupriya

AU - Tarlock, Katherine

AU - Meshinchi, Soheil

AU - Druker, Brian

AU - Tognon, Cristina E.

PY - 2017

Y1 - 2017

N2 - The ability to assess antileukemic drug activity on primary patient samples is a powerful tool in determining potential drug targets and selection of therapeutic agents with biological and functional rationale. We previously established small molecule inhibitor screens for use on freshly isolated leukemia cells for this purpose. Here we describe a method that produces functional small molecule inhibitor screening results using cryopreserved primary acute myeloid leukemia cells. This method was established to take advantage of biorepositories containing archival material, such as those established by the Children's Oncology Group, and to enable validation of potential pathway dependencies uncovered by genomic analysis. Various conditions used to thaw and culture cryopreserved specimens were assessed for effect on viability, differentiation, and the ability to recapitulate sensitivity results obtained on fresh samples. The most reproducible results were obtained by quick-thawing and culturing samples in cytokine rich media before performing drug screens. Our data suggest that cytokine-enriched media AIDS in maintaining the viability and numbers required to perform functional analysis on cryopreserved leukemia cells. This method can aid in producing informative data on therapeutic targeting and precision medicine efforts in leukemia by making use of biorepositories and bio banks.

AB - The ability to assess antileukemic drug activity on primary patient samples is a powerful tool in determining potential drug targets and selection of therapeutic agents with biological and functional rationale. We previously established small molecule inhibitor screens for use on freshly isolated leukemia cells for this purpose. Here we describe a method that produces functional small molecule inhibitor screening results using cryopreserved primary acute myeloid leukemia cells. This method was established to take advantage of biorepositories containing archival material, such as those established by the Children's Oncology Group, and to enable validation of potential pathway dependencies uncovered by genomic analysis. Various conditions used to thaw and culture cryopreserved specimens were assessed for effect on viability, differentiation, and the ability to recapitulate sensitivity results obtained on fresh samples. The most reproducible results were obtained by quick-thawing and culturing samples in cytokine rich media before performing drug screens. Our data suggest that cytokine-enriched media AIDS in maintaining the viability and numbers required to perform functional analysis on cryopreserved leukemia cells. This method can aid in producing informative data on therapeutic targeting and precision medicine efforts in leukemia by making use of biorepositories and bio banks.

KW - acute myeloid leukemia (AML)

KW - biorepositories

KW - cryopreservation

KW - small molecule inhibitor assays

UR - http://www.scopus.com/inward/record.url?scp=85030753955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030753955&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000946

DO - 10.1097/MPH.0000000000000946

M3 - Article

C2 - 28906323

AN - SCOPUS:85030753955

VL - 39

SP - e359-e366

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 7

ER -